GleamWall
中文EN

INTI Inhibitor Therapeutics, Inc.

Pharmaceutical Preparations · OTC · SEC CIK 1042418 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY7.0%
TTM EPS YoY0.0%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE—
ROA-188.4%
ROIC (approx.)—
Asset turnover—

Leverage & solvency

Liabilities / assets1,373.4%
Debt / equity—
Current ratio0.53x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.89x
Accruals ratio-21.0%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue————————
R&D expense$228,341$223,564$340,562$757,248$377,789$325,623$236,058$887,794
SG&A expense$363,684$395,033$355,070$557,866$363,426$370,150$438,493$596,455
Operating income-$592,025-$618,597-$695,632-$1.32M-$741,215-$695,773-$674,551-$1.48M
Net income-$590,380-$613,933-$686,425-$1.30M-$712,184-$659,942-$632,846-$1.42M
EPS (basic)0.000.000.00—0.000.000.00—
EPS (diluted)0.000.000.00—0.000.000.00—
Weighted avg. shares (diluted)173.79M173.31M172.57M—172.57M172.57M172.32M—
Balance sheet
Cash & equivalents$146,193$515,758$1.29M$2.38M$2.98M$3.74M$4.32M$5.61M
Current assets$204,123$586,806$1.38M$2.45M$3.06M$3.83M$4.42M$5.69M
Total assets$247,348$637,190$1.43M$2.51M$3.14M$3.91M$4.51M$5.69M
Current liabilities$383,394$174,894$382,320$766,330$87,533$139,961$94,712$709,618
Short-term debt$30,577$26,262$28,981$24,724$27,455$25,987$25,987—
Long-term debt$13,604$21,566$29,380$36,889$44,181$52,064$58,361—
Total debt$44,181$47,828$58,361$61,613$71,636$78,051$84,348—
Total liabilities$3.40M$3.20M$3.41M$3.80M$3.13M$3.19M$3.15M$3.71M
Shareholders' equity-$3.15M-$2.56M-$1.98M-$1.29M$3,453$715,637$1.35M$1.99M
Net debt-$102,012-$467,930-$1.23M-$2.31M-$2.91M-$3.66M-$4.24M—
Shares outstanding173.79M173.79M172.57M172.57M172.57M172.57M172.32M172.32M
Cash flow statement
Operating cash flow-$369,565-$775,220-$1.08M-$601,165-$761,245-$583,991-$1.28M-$771,441
Stock-based compensation$0——$0$0——$0

Free plan shows the latest 8 periods; Pro shows all 57 🔒

· This company does not report gross profit in XBRL.

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.